A phase IIa trial to assess the safety and efficacy of BL-8040 and pembrolizumab in patients with metastatic pancreatic adenocarcinoma (PDAC)
Manuel Hidalgo(Hospital Universitario de Fuenlabrada), Daniel D. Von Hoff(Translational Genomics Research Institute), Mitesh J. Borad(Jacksonville College), Ella Sorani, Osnat Kashtan(Protalix BioTherapeutics (Israel)), Katia Schlienger(United States Military Academy), Olivia Rosenfeld(Protalix BioTherapeutics (Israel)), Joon Oh Park(Samsung Medical Center), Brian M. Wolpin(Harvard University), Katrina S. Pedersen(Mayo Clinic in Arizona), Abi Vainstein Haras, Robert A. Ramirez(Vanderbilt University Medical Center), Erkut Borazanci(HonorHealth), Amnon Peled(Hebrew University of Jerusalem), Ron Epelbaum(University of Bern), Talia Golan(Sheba Medical Center), Tzipora M Lustig, Ravit Geva(Tel Aviv Sourasky Medical Center), Salomon M. Stemmer(Tel Aviv University)
Cited by 4
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
|Journal of Clinical Oncology|1997|5.9k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k